Review



nalm6 cells  (DSMZ)


Bioz Verified Symbol DSMZ is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    DSMZ nalm6 cells
    ( A ) Overview of cytosolic formaldehyde (FA) catabolism. ( B ) Heatmap depicting Log10 of the 50% FA inhibitory concentration (IC 50 ) in the presence or absence of l -buthionine-sulfoximine (BSO) at concentrations of 25 μM (H2170 cells), 50 μM <t>(Jurkat,</t> <t>Nalm6,</t> K562, and LUDLU-1 cells) or 100 μM (HCT116, H1299, A549, and T98G cells). ( C ) Representative FA viability curves normalized (norm.) to 0 μM FA for H1299 and A549 cells [mean ± SEM, n = 5 (H1299), n = 6 (A549), and two-way ANOVA (Tukey test between untreated (UT) and 100 μM BSO); for H1299: ** P = 0.0016, **** P < 0.0001, and ** P = 0.0023]. ( D ) Glutathione (GSH) levels upon 24-hour exposure to BSO [same concentrations as (B)] (mean ± SEM, n represented as dots, t test comparison between UT and BSO; * P = 0.0142, ** P = 0.0073, **** P < 0.0001). ( E ) Colony survival assay (CSA) in HCT116, H1299, and A549 in the presence of FA and/or 3.12 μM BSO for H1299 cells and 6.25 μM BSO for both HCT116 and A549 cells [mean ± SEM, n represented as dots, one-way ANOVA (Tukey test); for HCT116: **** P < 0.0001; for H1299: * P = 0.0106 and ** P = 0.0033]. ( F ) Left: GSH quantification in A549 cells expressing a nontargeting-control sgRNA (sgNTC) or sgRNAs against GSS (sg GSS ). Right: Viability in response to FA [mean ± SEM, n = 3]. ( G ) Immunoblots in A549 cells carrying an empty vector (pEV) or a vector coding for wild-type KEAP1 (p KEAP1 ). ( H ) Viability curves for A549/pEV or A549/pKEAP1 cells exposed to different concentrations of FA in the presence of 100 μM BSO [mean ± SEM, n = 3 and two-way ANOVA (Tukey test between UT and 100 μM BSO); **** P < 0.0001]. ( I ) DNA-protein cross-link (DPC) accumulation in A549/pEV and A549/pKEAP1 cells exposed to 100 μM BSO for 48 hours and to the indicated concentrations of FA for 4 hours (mean ± SEM, n = 3, one-way ANOVA in each cell line corrected by Tukey test) . Created in BioRender. https://BioRender.com/tsuwhsf .
    Nalm6 Cells, supplied by DSMZ, used in various techniques. Bioz Stars score: 97/100, based on 498 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nalm6/NALM-6/pmc13693651-162-0-8
    Average 97 stars, based on 498 article reviews
    nalm6 cells - by Bioz Stars, 2026-11
    97/100 stars

    Images

    1) Product Images from "NRF2 coordinates cystine import and glutathione use to sustain ferroptosis resistance and formaldehyde tolerance in cancer"

    Article Title: NRF2 coordinates cystine import and glutathione use to sustain ferroptosis resistance and formaldehyde tolerance in cancer

    Journal: Science Advances

    doi: 10.1126/sciadv.aea1431

    ( A ) Overview of cytosolic formaldehyde (FA) catabolism. ( B ) Heatmap depicting Log10 of the 50% FA inhibitory concentration (IC 50 ) in the presence or absence of l -buthionine-sulfoximine (BSO) at concentrations of 25 μM (H2170 cells), 50 μM (Jurkat, Nalm6, K562, and LUDLU-1 cells) or 100 μM (HCT116, H1299, A549, and T98G cells). ( C ) Representative FA viability curves normalized (norm.) to 0 μM FA for H1299 and A549 cells [mean ± SEM, n = 5 (H1299), n = 6 (A549), and two-way ANOVA (Tukey test between untreated (UT) and 100 μM BSO); for H1299: ** P = 0.0016, **** P < 0.0001, and ** P = 0.0023]. ( D ) Glutathione (GSH) levels upon 24-hour exposure to BSO [same concentrations as (B)] (mean ± SEM, n represented as dots, t test comparison between UT and BSO; * P = 0.0142, ** P = 0.0073, **** P < 0.0001). ( E ) Colony survival assay (CSA) in HCT116, H1299, and A549 in the presence of FA and/or 3.12 μM BSO for H1299 cells and 6.25 μM BSO for both HCT116 and A549 cells [mean ± SEM, n represented as dots, one-way ANOVA (Tukey test); for HCT116: **** P < 0.0001; for H1299: * P = 0.0106 and ** P = 0.0033]. ( F ) Left: GSH quantification in A549 cells expressing a nontargeting-control sgRNA (sgNTC) or sgRNAs against GSS (sg GSS ). Right: Viability in response to FA [mean ± SEM, n = 3]. ( G ) Immunoblots in A549 cells carrying an empty vector (pEV) or a vector coding for wild-type KEAP1 (p KEAP1 ). ( H ) Viability curves for A549/pEV or A549/pKEAP1 cells exposed to different concentrations of FA in the presence of 100 μM BSO [mean ± SEM, n = 3 and two-way ANOVA (Tukey test between UT and 100 μM BSO); **** P < 0.0001]. ( I ) DNA-protein cross-link (DPC) accumulation in A549/pEV and A549/pKEAP1 cells exposed to 100 μM BSO for 48 hours and to the indicated concentrations of FA for 4 hours (mean ± SEM, n = 3, one-way ANOVA in each cell line corrected by Tukey test) . Created in BioRender. https://BioRender.com/tsuwhsf .
    Figure Legend Snippet: ( A ) Overview of cytosolic formaldehyde (FA) catabolism. ( B ) Heatmap depicting Log10 of the 50% FA inhibitory concentration (IC 50 ) in the presence or absence of l -buthionine-sulfoximine (BSO) at concentrations of 25 μM (H2170 cells), 50 μM (Jurkat, Nalm6, K562, and LUDLU-1 cells) or 100 μM (HCT116, H1299, A549, and T98G cells). ( C ) Representative FA viability curves normalized (norm.) to 0 μM FA for H1299 and A549 cells [mean ± SEM, n = 5 (H1299), n = 6 (A549), and two-way ANOVA (Tukey test between untreated (UT) and 100 μM BSO); for H1299: ** P = 0.0016, **** P < 0.0001, and ** P = 0.0023]. ( D ) Glutathione (GSH) levels upon 24-hour exposure to BSO [same concentrations as (B)] (mean ± SEM, n represented as dots, t test comparison between UT and BSO; * P = 0.0142, ** P = 0.0073, **** P < 0.0001). ( E ) Colony survival assay (CSA) in HCT116, H1299, and A549 in the presence of FA and/or 3.12 μM BSO for H1299 cells and 6.25 μM BSO for both HCT116 and A549 cells [mean ± SEM, n represented as dots, one-way ANOVA (Tukey test); for HCT116: **** P < 0.0001; for H1299: * P = 0.0106 and ** P = 0.0033]. ( F ) Left: GSH quantification in A549 cells expressing a nontargeting-control sgRNA (sgNTC) or sgRNAs against GSS (sg GSS ). Right: Viability in response to FA [mean ± SEM, n = 3]. ( G ) Immunoblots in A549 cells carrying an empty vector (pEV) or a vector coding for wild-type KEAP1 (p KEAP1 ). ( H ) Viability curves for A549/pEV or A549/pKEAP1 cells exposed to different concentrations of FA in the presence of 100 μM BSO [mean ± SEM, n = 3 and two-way ANOVA (Tukey test between UT and 100 μM BSO); **** P < 0.0001]. ( I ) DNA-protein cross-link (DPC) accumulation in A549/pEV and A549/pKEAP1 cells exposed to 100 μM BSO for 48 hours and to the indicated concentrations of FA for 4 hours (mean ± SEM, n = 3, one-way ANOVA in each cell line corrected by Tukey test) . Created in BioRender. https://BioRender.com/tsuwhsf .

    Techniques Used: Concentration Assay, Comparison, Clonogenic Cell Survival Assay, Expressing, Control, Western Blot, Plasmid Preparation

    Related Articles

    Cell Culture:

    Article Title: Exploitation of the fibrinolytic system by B-cell acute lymphoblastic leukemia and its therapeutic targeting.
    Article Snippet: Cells were transduced on two consecutive days with cryopreserved MSCV-IRES-GFP (empty vector), MSCV-IRES GFP BCRABL1- (as in vitro model for murine B-ALL) or MSCV-IRES GFP MLLAF9- (as in vitro model for murine AML) expressing retroviri. .. The human leukemic cell lines K562 (BCR-ABL1+; myeloid, model of CML) (ACC10), NALM6 (lymphoid, model of BCR-ABL1-negative BALL) (ACC128), THP1 (MLL-AF9+; myeloid, model of AML) (ACC16), SUPB15 (lymphoid, model of BCR-ABL1-positive B-ALL) (ACC389) and Kasumi (AML1-ETO+; myeloid, model of AML) (ACC220) were purchased from the DSMZ and cultured in RPMI, 10% FBS, 1% penicillin/streptomycin and 1% L-glutamine. ..

    Article Title: High-throughput ligand diversification to discover chemical inducers of proximity.
    Article Snippet: OCI-AML2 (gift from J. Bradner), OCI-AML3 (German Collection of Microorganisms and Cell Cultures (DSMZ), ACC 582) and Kasumi-1 (American Type Culture Collection (ATCC), CRL-2724) were cultured in 20% FBS in RPMI 1640. .. HB11;19 (gift from the laboratory of A. Yokoyama), Jurkat (gift of the laboratory of M. Bollong) MV4;11 and MOLM-13 (gifts from J. Bradner), NALM6 (given by ChemoGenix, University of Montreal) and EOL1 (DSMZ, ACC 386) cells were cultured in 10% FBS in RPMI 1640. .. RPE1 (ATCC, CRL-4000), HEK293T (ATCC, CRL3216) and Lenti-X 293T (Takara Bio, 632180) cells were cultured in 10% FBS in DMEM.

    Article Title: Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR
    Article Snippet: HEK-293T (ATCC;ATCCCRL-11268)were cultured in Iscove’smodifiedDulbecco’smedium(12-726F, Lonza) supplementedwith 10%FBS (Labtech) and 2 mM GlutaMAX (35050061, Invitrogen). .. SupT1 (ECACC; 95013123), NALM6 (DSMZ; ACC 128) and Raji (ATCC, ATCC CCL-86) lines were cultured in complete RPMI (RPMI-1640, Lonza) supplemented with 10% FBS and 2 mM GlutaMAX. .. Flow cytometry was performed using MACSQuant 10 and X flow cytometers (Miltenyi Biotec).

    other:

    Article Title: iPSC-derived trimodal T cells engineered with CAR, TCR, and hnCD16 modalities can overcome antigen escape in heterogeneous tumors.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies anti-human CD2 BioLegend 300230; RRID:AB_2800713 anti-human CD3 Biolegend 317330; RRID:AB_11219196 anti-human CD4 BioLegend 344631; RRID:AB_2566014 anti-human CD5 BD Bioscience 555352; RRID:AB_395756 anti-human CD7 BD Bioscience 555361; RRID:AB_395764 anti-human CD8a BD Bioscience 612754; RRID:AB_2870085 anti-human CD8b eBioscience 25-5273-42; RRID:AB_11219680 anti-human CD10 BD Bioscience 564960; RRID:AB_2739025 anti-human CD107a BD Bioscience 555800; RRID:AB_396134 anti-human CD107b BD Bioscience 555804; RRID:AB_396138 anti-human CD16 BD Bioscience 556619; RRID:AB_396491 anti-human CD25 BioLegend 356140; RRID:AB_2750205 anti-human CD27 BioLegend 356404; RRID:AB_2561788 anti-human CD28 BioLegend 302908; RRID:AB_314310 anti-human CD30 BD Bioscience 550041; RRID:AB_393541 anti-human CD38 BioLegend 397104; RRID:AB_2810611 anti-human CD45 BD Bioscience 563792; RRID:AB_2869519 anti-human CD45RA BD Bioscience 555488; RRID:AB_395879 anti-human CD62L BD Bioscience 559772; RRID:AB_398668 anti-human LAG3 BioLegend 369310; RRID:AB_2629753 anti-human PD1 eBioscience 12-2799-42; RRID:AB_11042478 anti-human MICA/B (clone 7C6) Andrade et al. 30 N/A anti-human SSEA4 BD Bioscience 560126; RRID:AB_1645491 anti-human TCRv13.1 Beckman Coulter IM2292 anti-human TIM3 BioLegend 345016; RRID:AB_2561934 anti-human TRA181 BD Bioscience 560793; RRID:AB_10550550 anti-ID BCMA CAR This paper N/A anti-human pCD3z BD Bioscience 558486; RRID:AB_647104 anti-human pERK BD biosciences 612593; RRID:AB_399876 anti-human pLAT BD biosciences 558518; RRID:AB_647131 anti-human pSLP76 BD biosciences 558439; RRID:AB_647107 anti-human pZAP70 BD biosciences 557818; RRID:AB_396885 anti-human Interferon-γ Biolegend 502532; RRID:AB_2561398 anti-human TNFα Biolegend 502948; RRID:AB_2565858 human Fc Block BD Bioscience 564220; RRID:AB_2869554 mouse Fc Block BD Bioscience 553142; RRID:AB_394657 anti-mouse CD90.1 BioLegend 202529; RRID:AB_10899572 Biotinylated anti-human CD16 antibody Biolegend 302004; RRID:AB_314203 anti-CD19 (MDX-1342) antibody Creative Biolabs AFC-104CL anti-PD-L1 (Avelumab) antibody MedChemExpress HY-108730 anti-EGFR (Cetuximab) antibody MedChemExpress HY-P9905 Anti-HER2 (Herceptin) antibody Roche PZN-01289787 anti-CD38 (Daratumumab) antibody DARZALEX DARZALEX (Continued on next page) e1 Cell Reports Medicine 6, 102195, July 15, 2025 OPEN ACCESS

    Article Title: iPSC-derived trimodal T cells engineered with CAR, TCR, and hnCD16 modalities can overcome antigen escape in heterogeneous tumors
    Article Snippet: Female 6-8 weeks old NSG mice (NOD.Cg- Prkdc scid Il2rg tm1Wjl /SzJ) were purchased from The Jackson Laboratory (RRID:IMSR, Cat. 005557).



    Similar Products

    nalm 6  (ATCC)
    96
    ATCC nalm 6
    Nalm 6, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nalm6/NALM6%2C+clone+G5/pmc13772839-89-6-14
    Average 96 stars, based on 1 article reviews
    nalm 6 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    nalm6  (ATCC)
    99
    ATCC nalm6
    A Gene (left) and protein (right) schematics of the chimeric NCR1 and KIR3DS1 receptors with CD8α transmembrane domain or transmembrane domain mutation. B Membrane surface expression of chimeric NCR1 receptors on NK92MI cell line determined by flow cytometry. ( C and D ) Normalized IFN-γ secretion of chimeric NCR1 receptors engineered NK92MI cells upon <t>Nalm6</t> C and <t>Raji</t> ( D ) cells stimulation for 24 hours at an effector:target (E:T) ratio of 1:5. E Membrane surface expression of chimeric KIR3DS1 receptors on NK92MI cell line determined by flow cytometry. ( F and G ) Normalized IFN-γ secretion of chimeric NCR1 receptors engineered NK92MI cells upon Nalm6 F and Raji ( G ) cells stimulation for 24 hours at an effector:target (E:T) ratio of 1:5. Data are presented as mean with SD (n = 3; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001; ns, nonsignificant; unpaired two-tailed Student’s t-test for comparisons).
    Nalm6, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nalm6/Raji/bio_rxiv__64898__2026__11__02__763574-159-5-11
    Average 99 stars, based on 1 article reviews
    nalm6 - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    96
    ATCC nalm6 leukemia cells
    a–c , Surface CAR density (a), peak IFN-γ across eight E:T ratios (b) and killing of H929 myeloma cells (c) by primary T cells expressing bb2121 BCMA CARs. d–f , The same ICDs in FMC63 CD19 CARs: surface CAR density (d), peak IFN-γ across eight E:T ratios (e) and killing of <t>NALM6</t> leukemia cells (f). Rows in b and e follow a and d. Killing is shown as residual target-cell luminescence normalized to the lowest E:T ratio for each construct and replicate; lower values indicate more killing. g , Peak IFN-γ from BCMA CAR T cells without targets across eight effector inputs; dotted line (LLOD), 9.8 pg/mL lower limit of detection. h , Jurkat NFAT and NF-κB responses to costimulation- or ITAM-disrupting mutations in brs–ζ1–40 and BBζ ( 4-1BB– CD3ζ ). In brs–ζ1–40 , E42A/E45A substitutions alter the CD40-derived TRAF6-binding segment (QEPQE→QAPQA), and Y21F/Y32F substitutions replace both ITAM1 tyrosines. The corresponding BBζ mutants disrupt 4-1BB costimulation or replace all six tyrosines across the three CD3ζ ITAMs with phenylalanine. i , Three binder formats, and brs–ζ1–40 vs. BBζ expression across them. j , Zero-shot LLM predictions for the round 1 library against NFAT relative to BBζ ; mean of five models.
    Nalm6 Leukemia Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nalm6/NALM6%2C+clone+G5/bio_rxiv__64898__2026__10__28__762481-284-0-3
    Average 96 stars, based on 1 article reviews
    nalm6 leukemia cells - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    97
    DSMZ nalm6 cells
    ( A ) Overview of cytosolic formaldehyde (FA) catabolism. ( B ) Heatmap depicting Log10 of the 50% FA inhibitory concentration (IC 50 ) in the presence or absence of l -buthionine-sulfoximine (BSO) at concentrations of 25 μM (H2170 cells), 50 μM <t>(Jurkat,</t> <t>Nalm6,</t> K562, and LUDLU-1 cells) or 100 μM (HCT116, H1299, A549, and T98G cells). ( C ) Representative FA viability curves normalized (norm.) to 0 μM FA for H1299 and A549 cells [mean ± SEM, n = 5 (H1299), n = 6 (A549), and two-way ANOVA (Tukey test between untreated (UT) and 100 μM BSO); for H1299: ** P = 0.0016, **** P < 0.0001, and ** P = 0.0023]. ( D ) Glutathione (GSH) levels upon 24-hour exposure to BSO [same concentrations as (B)] (mean ± SEM, n represented as dots, t test comparison between UT and BSO; * P = 0.0142, ** P = 0.0073, **** P < 0.0001). ( E ) Colony survival assay (CSA) in HCT116, H1299, and A549 in the presence of FA and/or 3.12 μM BSO for H1299 cells and 6.25 μM BSO for both HCT116 and A549 cells [mean ± SEM, n represented as dots, one-way ANOVA (Tukey test); for HCT116: **** P < 0.0001; for H1299: * P = 0.0106 and ** P = 0.0033]. ( F ) Left: GSH quantification in A549 cells expressing a nontargeting-control sgRNA (sgNTC) or sgRNAs against GSS (sg GSS ). Right: Viability in response to FA [mean ± SEM, n = 3]. ( G ) Immunoblots in A549 cells carrying an empty vector (pEV) or a vector coding for wild-type KEAP1 (p KEAP1 ). ( H ) Viability curves for A549/pEV or A549/pKEAP1 cells exposed to different concentrations of FA in the presence of 100 μM BSO [mean ± SEM, n = 3 and two-way ANOVA (Tukey test between UT and 100 μM BSO); **** P < 0.0001]. ( I ) DNA-protein cross-link (DPC) accumulation in A549/pEV and A549/pKEAP1 cells exposed to 100 μM BSO for 48 hours and to the indicated concentrations of FA for 4 hours (mean ± SEM, n = 3, one-way ANOVA in each cell line corrected by Tukey test) . Created in BioRender. https://BioRender.com/tsuwhsf .
    Nalm6 Cells, supplied by DSMZ, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nalm6/NALM-6/pmc13693651-162-0-8
    Average 97 stars, based on 1 article reviews
    nalm6 cells - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    96
    ATCC cd19 human b cell precursor 428 leukemia line nalm6
    ( A ) Overview of cytosolic formaldehyde (FA) catabolism. ( B ) Heatmap depicting Log10 of the 50% FA inhibitory concentration (IC 50 ) in the presence or absence of l -buthionine-sulfoximine (BSO) at concentrations of 25 μM (H2170 cells), 50 μM <t>(Jurkat,</t> <t>Nalm6,</t> K562, and LUDLU-1 cells) or 100 μM (HCT116, H1299, A549, and T98G cells). ( C ) Representative FA viability curves normalized (norm.) to 0 μM FA for H1299 and A549 cells [mean ± SEM, n = 5 (H1299), n = 6 (A549), and two-way ANOVA (Tukey test between untreated (UT) and 100 μM BSO); for H1299: ** P = 0.0016, **** P < 0.0001, and ** P = 0.0023]. ( D ) Glutathione (GSH) levels upon 24-hour exposure to BSO [same concentrations as (B)] (mean ± SEM, n represented as dots, t test comparison between UT and BSO; * P = 0.0142, ** P = 0.0073, **** P < 0.0001). ( E ) Colony survival assay (CSA) in HCT116, H1299, and A549 in the presence of FA and/or 3.12 μM BSO for H1299 cells and 6.25 μM BSO for both HCT116 and A549 cells [mean ± SEM, n represented as dots, one-way ANOVA (Tukey test); for HCT116: **** P < 0.0001; for H1299: * P = 0.0106 and ** P = 0.0033]. ( F ) Left: GSH quantification in A549 cells expressing a nontargeting-control sgRNA (sgNTC) or sgRNAs against GSS (sg GSS ). Right: Viability in response to FA [mean ± SEM, n = 3]. ( G ) Immunoblots in A549 cells carrying an empty vector (pEV) or a vector coding for wild-type KEAP1 (p KEAP1 ). ( H ) Viability curves for A549/pEV or A549/pKEAP1 cells exposed to different concentrations of FA in the presence of 100 μM BSO [mean ± SEM, n = 3 and two-way ANOVA (Tukey test between UT and 100 μM BSO); **** P < 0.0001]. ( I ) DNA-protein cross-link (DPC) accumulation in A549/pEV and A549/pKEAP1 cells exposed to 100 μM BSO for 48 hours and to the indicated concentrations of FA for 4 hours (mean ± SEM, n = 3, one-way ANOVA in each cell line corrected by Tukey test) . Created in BioRender. https://BioRender.com/tsuwhsf .
    Cd19 Human B Cell Precursor 428 Leukemia Line Nalm6, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nalm6/NALM6%2C+clone+G5/pm42888846-174-1-36
    Average 96 stars, based on 1 article reviews
    cd19 human b cell precursor 428 leukemia line nalm6 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    ATCC cell line nalm6
    ( A ) Overview of cytosolic formaldehyde (FA) catabolism. ( B ) Heatmap depicting Log10 of the 50% FA inhibitory concentration (IC 50 ) in the presence or absence of l -buthionine-sulfoximine (BSO) at concentrations of 25 μM (H2170 cells), 50 μM <t>(Jurkat,</t> <t>Nalm6,</t> K562, and LUDLU-1 cells) or 100 μM (HCT116, H1299, A549, and T98G cells). ( C ) Representative FA viability curves normalized (norm.) to 0 μM FA for H1299 and A549 cells [mean ± SEM, n = 5 (H1299), n = 6 (A549), and two-way ANOVA (Tukey test between untreated (UT) and 100 μM BSO); for H1299: ** P = 0.0016, **** P < 0.0001, and ** P = 0.0023]. ( D ) Glutathione (GSH) levels upon 24-hour exposure to BSO [same concentrations as (B)] (mean ± SEM, n represented as dots, t test comparison between UT and BSO; * P = 0.0142, ** P = 0.0073, **** P < 0.0001). ( E ) Colony survival assay (CSA) in HCT116, H1299, and A549 in the presence of FA and/or 3.12 μM BSO for H1299 cells and 6.25 μM BSO for both HCT116 and A549 cells [mean ± SEM, n represented as dots, one-way ANOVA (Tukey test); for HCT116: **** P < 0.0001; for H1299: * P = 0.0106 and ** P = 0.0033]. ( F ) Left: GSH quantification in A549 cells expressing a nontargeting-control sgRNA (sgNTC) or sgRNAs against GSS (sg GSS ). Right: Viability in response to FA [mean ± SEM, n = 3]. ( G ) Immunoblots in A549 cells carrying an empty vector (pEV) or a vector coding for wild-type KEAP1 (p KEAP1 ). ( H ) Viability curves for A549/pEV or A549/pKEAP1 cells exposed to different concentrations of FA in the presence of 100 μM BSO [mean ± SEM, n = 3 and two-way ANOVA (Tukey test between UT and 100 μM BSO); **** P < 0.0001]. ( I ) DNA-protein cross-link (DPC) accumulation in A549/pEV and A549/pKEAP1 cells exposed to 100 μM BSO for 48 hours and to the indicated concentrations of FA for 4 hours (mean ± SEM, n = 3, one-way ANOVA in each cell line corrected by Tukey test) . Created in BioRender. https://BioRender.com/tsuwhsf .
    Cell Line Nalm6, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nalm6/NALM6%2C+clone+G5/pm42864416-37-18-29
    Average 96 stars, based on 1 article reviews
    cell line nalm6 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    DSMZ cell line nalm6
    ( A ) Overview of cytosolic formaldehyde (FA) catabolism. ( B ) Heatmap depicting Log10 of the 50% FA inhibitory concentration (IC 50 ) in the presence or absence of l -buthionine-sulfoximine (BSO) at concentrations of 25 μM (H2170 cells), 50 μM <t>(Jurkat,</t> <t>Nalm6,</t> K562, and LUDLU-1 cells) or 100 μM (HCT116, H1299, A549, and T98G cells). ( C ) Representative FA viability curves normalized (norm.) to 0 μM FA for H1299 and A549 cells [mean ± SEM, n = 5 (H1299), n = 6 (A549), and two-way ANOVA (Tukey test between untreated (UT) and 100 μM BSO); for H1299: ** P = 0.0016, **** P < 0.0001, and ** P = 0.0023]. ( D ) Glutathione (GSH) levels upon 24-hour exposure to BSO [same concentrations as (B)] (mean ± SEM, n represented as dots, t test comparison between UT and BSO; * P = 0.0142, ** P = 0.0073, **** P < 0.0001). ( E ) Colony survival assay (CSA) in HCT116, H1299, and A549 in the presence of FA and/or 3.12 μM BSO for H1299 cells and 6.25 μM BSO for both HCT116 and A549 cells [mean ± SEM, n represented as dots, one-way ANOVA (Tukey test); for HCT116: **** P < 0.0001; for H1299: * P = 0.0106 and ** P = 0.0033]. ( F ) Left: GSH quantification in A549 cells expressing a nontargeting-control sgRNA (sgNTC) or sgRNAs against GSS (sg GSS ). Right: Viability in response to FA [mean ± SEM, n = 3]. ( G ) Immunoblots in A549 cells carrying an empty vector (pEV) or a vector coding for wild-type KEAP1 (p KEAP1 ). ( H ) Viability curves for A549/pEV or A549/pKEAP1 cells exposed to different concentrations of FA in the presence of 100 μM BSO [mean ± SEM, n = 3 and two-way ANOVA (Tukey test between UT and 100 μM BSO); **** P < 0.0001]. ( I ) DNA-protein cross-link (DPC) accumulation in A549/pEV and A549/pKEAP1 cells exposed to 100 μM BSO for 48 hours and to the indicated concentrations of FA for 4 hours (mean ± SEM, n = 3, one-way ANOVA in each cell line corrected by Tukey test) . Created in BioRender. https://BioRender.com/tsuwhsf .
    Cell Line Nalm6, supplied by DSMZ, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nalm6/NALM-6/pm42844286-294-25-28
    Average 96 stars, based on 1 article reviews
    cell line nalm6 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    ATCC human acute lymphoblastic leukemia cell line nalm6
    (A). DT intoxication pathway. DT consists of a catalytic domain, a translocation domain and a receptor binding domain. Upon binding to its targeting receptor HBEGF, DT undergoes receptor-mediated endocytosis. The translocation domain facilitates endosomal escape and cytosolic delivery of the catalytic domain, which subsequently catalyzes the ADP ribosylation of elongation factor 2. This leads to inhibition of protein synthesis and ultimately cell death. (B). Schematic of DT-based immunotoxins. The native RBD of DT is swapped with a binder to cancer-associated receptors. CD123-, HER3- and HER2-targeted ITs are designed using either nanobodies (CD123) or affibodies (HER2 and HER3). For each targeted receptor, low- and high-affinity binders were formatted as either monovalent or bivalent RBDs, generating four different RBD configurations. (C). The impacts of affinity and avidity tuning on the therapeutic window of ITs. For each targeted receptor, ITs were tested on in paired receptor-high (red) and a receptor-low (gray) cell lines, with receptor abundance quantified by flow cytometry and indicated above each cell line. Representative dose-response curves are shown for the low-affinity monovalent ITs. The therapeutic window was defined as the ratio of EC50 in receptor-low over receptor-high cells. Black bars indicate the magnitude of therapeutic window, and the edge of the black bar represents the EC50 means. n=3, biological replicates.
    Human Acute Lymphoblastic Leukemia Cell Line Nalm6, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nalm6/NALM6%2C+clone+G5/bio_rxiv__64898__2026__09__27__754776-176-28-38
    Average 96 stars, based on 1 article reviews
    human acute lymphoblastic leukemia cell line nalm6 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    Image Search Results


    A Gene (left) and protein (right) schematics of the chimeric NCR1 and KIR3DS1 receptors with CD8α transmembrane domain or transmembrane domain mutation. B Membrane surface expression of chimeric NCR1 receptors on NK92MI cell line determined by flow cytometry. ( C and D ) Normalized IFN-γ secretion of chimeric NCR1 receptors engineered NK92MI cells upon Nalm6 C and Raji ( D ) cells stimulation for 24 hours at an effector:target (E:T) ratio of 1:5. E Membrane surface expression of chimeric KIR3DS1 receptors on NK92MI cell line determined by flow cytometry. ( F and G ) Normalized IFN-γ secretion of chimeric NCR1 receptors engineered NK92MI cells upon Nalm6 F and Raji ( G ) cells stimulation for 24 hours at an effector:target (E:T) ratio of 1:5. Data are presented as mean with SD (n = 3; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001; ns, nonsignificant; unpaired two-tailed Student’s t-test for comparisons).

    Journal: bioRxiv

    Article Title: A biomimetic SPARC platform coupling adaptor recruitment and BRS-Lck condensation for enhanced NK/T cell combination therapy

    doi: 10.64898/2026.11.02.763574

    Figure Lengend Snippet: A Gene (left) and protein (right) schematics of the chimeric NCR1 and KIR3DS1 receptors with CD8α transmembrane domain or transmembrane domain mutation. B Membrane surface expression of chimeric NCR1 receptors on NK92MI cell line determined by flow cytometry. ( C and D ) Normalized IFN-γ secretion of chimeric NCR1 receptors engineered NK92MI cells upon Nalm6 C and Raji ( D ) cells stimulation for 24 hours at an effector:target (E:T) ratio of 1:5. E Membrane surface expression of chimeric KIR3DS1 receptors on NK92MI cell line determined by flow cytometry. ( F and G ) Normalized IFN-γ secretion of chimeric NCR1 receptors engineered NK92MI cells upon Nalm6 F and Raji ( G ) cells stimulation for 24 hours at an effector:target (E:T) ratio of 1:5. Data are presented as mean with SD (n = 3; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001; ns, nonsignificant; unpaired two-tailed Student’s t-test for comparisons).

    Article Snippet: Human cancer cell lines Jurkat, Nalm6 and Raji were obtained from ATCC.

    Techniques: Mutagenesis, Membrane, Expressing, Flow Cytometry, Two Tailed Test

    A Gene schematics of the chimeric NCR1 receptors with CD8α stalk and TCRα mutation transmembrane domain. B Surface expression of SPARCs in ( A ) on NK92MI cells by flow cytometry. C Cytokine productions of SPARC-NK92MI cells upon Nalm6 cells stimulation for 24 hours at the indicated effector:target (E:T) ratios. IFN-γ (left) and TNF-α (right) were measured. D Surface expression of SPARC-Jurkat cells by flow cytometry. E IL-2 secretion of SPARC-Jurkat cells upon Raji cells stimulation for 24 hours. Data are presented as mean with SD (n = 3; ∗, P < 0.05; ∗∗, P < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001; ns, nonsignificant; unpaired two-tailed Student’s t-test for comparisons).

    Journal: bioRxiv

    Article Title: A biomimetic SPARC platform coupling adaptor recruitment and BRS-Lck condensation for enhanced NK/T cell combination therapy

    doi: 10.64898/2026.11.02.763574

    Figure Lengend Snippet: A Gene schematics of the chimeric NCR1 receptors with CD8α stalk and TCRα mutation transmembrane domain. B Surface expression of SPARCs in ( A ) on NK92MI cells by flow cytometry. C Cytokine productions of SPARC-NK92MI cells upon Nalm6 cells stimulation for 24 hours at the indicated effector:target (E:T) ratios. IFN-γ (left) and TNF-α (right) were measured. D Surface expression of SPARC-Jurkat cells by flow cytometry. E IL-2 secretion of SPARC-Jurkat cells upon Raji cells stimulation for 24 hours. Data are presented as mean with SD (n = 3; ∗, P < 0.05; ∗∗, P < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001; ns, nonsignificant; unpaired two-tailed Student’s t-test for comparisons).

    Article Snippet: Human cancer cell lines Jurkat, Nalm6 and Raji were obtained from ATCC.

    Techniques: Mutagenesis, Expressing, Flow Cytometry, Two Tailed Test

    A Gene (left) and protein (right) schematics of the SPARC with 4-1BB co-stimulatory domain and BBz CAR. B Surface expression of SPARC and CAR on NK92MI cells by flow cytometry. C Cytokine productions of SPARC-NK92MI cells upon Nalm6 cells stimulation for 24 hours at the indicated effector:target (E:T) ratios. IFN-γ (left) and TNF-α (right) were measured. D Schematic representation of the in vitro experiment for primary T cells and NK92MI cells combined therapy. E Surface expression of SPARCs and CAR on primary T cells by flow cytometry. F IFN-γ secretion in the supernatants from co-culture of SPARC- and CAR-NK92MI cells and T cells upon Raji cells stimulation for 24 hours at the indicated cell numbers. Raji cells is 20000 per well. Data are presented as mean with SD (n = 3; ∗, P < 0.05; ns, nonsignificant; unpaired two-tailed Student’s t-test for comparisons).

    Journal: bioRxiv

    Article Title: A biomimetic SPARC platform coupling adaptor recruitment and BRS-Lck condensation for enhanced NK/T cell combination therapy

    doi: 10.64898/2026.11.02.763574

    Figure Lengend Snippet: A Gene (left) and protein (right) schematics of the SPARC with 4-1BB co-stimulatory domain and BBz CAR. B Surface expression of SPARC and CAR on NK92MI cells by flow cytometry. C Cytokine productions of SPARC-NK92MI cells upon Nalm6 cells stimulation for 24 hours at the indicated effector:target (E:T) ratios. IFN-γ (left) and TNF-α (right) were measured. D Schematic representation of the in vitro experiment for primary T cells and NK92MI cells combined therapy. E Surface expression of SPARCs and CAR on primary T cells by flow cytometry. F IFN-γ secretion in the supernatants from co-culture of SPARC- and CAR-NK92MI cells and T cells upon Raji cells stimulation for 24 hours at the indicated cell numbers. Raji cells is 20000 per well. Data are presented as mean with SD (n = 3; ∗, P < 0.05; ns, nonsignificant; unpaired two-tailed Student’s t-test for comparisons).

    Article Snippet: Human cancer cell lines Jurkat, Nalm6 and Raji were obtained from ATCC.

    Techniques: Expressing, Flow Cytometry, In Vitro, Co-culture Assay, Two Tailed Test

    A Gene (left) and protein (right) schematics of the SPARC with NCR1 and 4-1BB dual ICD, NCR1 R-A -NCR1BBz and CD8-NCR1BBz CAR. B IFN-γ productions of SPARC-NK92MI cells upon Nalm6 cells stimulation for 24 hours. C IL-2 productions of SPARC-T cells upon Raji cells stimulation for 24 hours. D IFN-γ secretion in the supernatants from co-culture of SPARC- and CAR-NK92MI cells and T cells upon Raji cells stimulation for 24 hours at the indicated cell numbers. Raji cells is 20000 per well. Data are presented as mean with SD (n = 3; ∗, P < 0.05; ∗∗, P < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001; ns, nonsignificant; unpaired two-tailed Student’s t-test for comparisons).

    Journal: bioRxiv

    Article Title: A biomimetic SPARC platform coupling adaptor recruitment and BRS-Lck condensation for enhanced NK/T cell combination therapy

    doi: 10.64898/2026.11.02.763574

    Figure Lengend Snippet: A Gene (left) and protein (right) schematics of the SPARC with NCR1 and 4-1BB dual ICD, NCR1 R-A -NCR1BBz and CD8-NCR1BBz CAR. B IFN-γ productions of SPARC-NK92MI cells upon Nalm6 cells stimulation for 24 hours. C IL-2 productions of SPARC-T cells upon Raji cells stimulation for 24 hours. D IFN-γ secretion in the supernatants from co-culture of SPARC- and CAR-NK92MI cells and T cells upon Raji cells stimulation for 24 hours at the indicated cell numbers. Raji cells is 20000 per well. Data are presented as mean with SD (n = 3; ∗, P < 0.05; ∗∗, P < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001; ns, nonsignificant; unpaired two-tailed Student’s t-test for comparisons).

    Article Snippet: Human cancer cell lines Jurkat, Nalm6 and Raji were obtained from ATCC.

    Techniques: Co-culture Assay, Two Tailed Test

    a–c , Surface CAR density (a), peak IFN-γ across eight E:T ratios (b) and killing of H929 myeloma cells (c) by primary T cells expressing bb2121 BCMA CARs. d–f , The same ICDs in FMC63 CD19 CARs: surface CAR density (d), peak IFN-γ across eight E:T ratios (e) and killing of NALM6 leukemia cells (f). Rows in b and e follow a and d. Killing is shown as residual target-cell luminescence normalized to the lowest E:T ratio for each construct and replicate; lower values indicate more killing. g , Peak IFN-γ from BCMA CAR T cells without targets across eight effector inputs; dotted line (LLOD), 9.8 pg/mL lower limit of detection. h , Jurkat NFAT and NF-κB responses to costimulation- or ITAM-disrupting mutations in brs–ζ1–40 and BBζ ( 4-1BB– CD3ζ ). In brs–ζ1–40 , E42A/E45A substitutions alter the CD40-derived TRAF6-binding segment (QEPQE→QAPQA), and Y21F/Y32F substitutions replace both ITAM1 tyrosines. The corresponding BBζ mutants disrupt 4-1BB costimulation or replace all six tyrosines across the three CD3ζ ITAMs with phenylalanine. i , Three binder formats, and brs–ζ1–40 vs. BBζ expression across them. j , Zero-shot LLM predictions for the round 1 library against NFAT relative to BBζ ; mean of five models.

    Journal: bioRxiv

    Article Title: Refactored intracellular domains enhance CAR expression and function

    doi: 10.64898/2026.10.28.762481

    Figure Lengend Snippet: a–c , Surface CAR density (a), peak IFN-γ across eight E:T ratios (b) and killing of H929 myeloma cells (c) by primary T cells expressing bb2121 BCMA CARs. d–f , The same ICDs in FMC63 CD19 CARs: surface CAR density (d), peak IFN-γ across eight E:T ratios (e) and killing of NALM6 leukemia cells (f). Rows in b and e follow a and d. Killing is shown as residual target-cell luminescence normalized to the lowest E:T ratio for each construct and replicate; lower values indicate more killing. g , Peak IFN-γ from BCMA CAR T cells without targets across eight effector inputs; dotted line (LLOD), 9.8 pg/mL lower limit of detection. h , Jurkat NFAT and NF-κB responses to costimulation- or ITAM-disrupting mutations in brs–ζ1–40 and BBζ ( 4-1BB– CD3ζ ). In brs–ζ1–40 , E42A/E45A substitutions alter the CD40-derived TRAF6-binding segment (QEPQE→QAPQA), and Y21F/Y32F substitutions replace both ITAM1 tyrosines. The corresponding BBζ mutants disrupt 4-1BB costimulation or replace all six tyrosines across the three CD3ζ ITAMs with phenylalanine. i , Three binder formats, and brs–ζ1–40 vs. BBζ expression across them. j , Zero-shot LLM predictions for the round 1 library against NFAT relative to BBζ ; mean of five models.

    Article Snippet: NALM6 leukemia cells (ATCC, CRL-3273), which we transduced with firefly luciferase lentivirus (BPS Bioscience, 79692-P), and Raji lymphoma cells (ATCC, CCL-86) were cultured in RPMI-1640 with 10% FBS and 1% penicillin– streptomycin.

    Techniques: Expressing, Construct, Derivative Assay, Binding Assay, Negative Control

    a , NFAT luminescence of brs–ζ1–40 and BBζ ( 4-1BB–CD3ζ ) without antigen and with BCMA-positive targets in each of two independent experiments. b , BCMA-stimulated NFAT for krgr–ζ1–4-1bb with (+KRGR) and without (−KRGR) its four N-terminal residues, relative to the same-plate BBζ (dashed line). Without KRGR, the first ITAM tyrosine (Y1) sits four residues closer to the membrane and the design did not function. c , d , H929-induced IFN-γ in replicate 1 against replicate 2, measured on separate plates; dashed line, identity; dotted lines, lower limit of detection; R 2 , squared Pearson correlation of log 10 values for wells above that limit (c, 74 wells; d, 73 wells). c , The primary T-cell re-screen of , which plots replicate 1: library designs (light gray circles), brs–ζ1–40 (orange diamond), BBζ (gray square) and negative controls (×). d , The BCMA CARs of : small open light-gray circles, non-peak E:T wells; filled circles, each design’s peak, as ranked in : brs–ζ1–40 (orange), krgr–ζ1–4-1bb (teal), BBζ (gray) and other designs (small, light gray). e , f , IFN-γ across the eight E:T ratios behind the peak values of (e; H929 targets, BCMA CARs; mean ± s.d. of the two replicate plates, or the single reading where only one exists) and (f; NALM6 targets, CD19 CARs; one well per E:T), with points joined without fitting: brs–ζ1–40 (orange diamonds), krgr–ζ1–4-1bb (teal triangles), BBζ (gray squares) and other designs (light gray circles).

    Journal: bioRxiv

    Article Title: Refactored intracellular domains enhance CAR expression and function

    doi: 10.64898/2026.10.28.762481

    Figure Lengend Snippet: a , NFAT luminescence of brs–ζ1–40 and BBζ ( 4-1BB–CD3ζ ) without antigen and with BCMA-positive targets in each of two independent experiments. b , BCMA-stimulated NFAT for krgr–ζ1–4-1bb with (+KRGR) and without (−KRGR) its four N-terminal residues, relative to the same-plate BBζ (dashed line). Without KRGR, the first ITAM tyrosine (Y1) sits four residues closer to the membrane and the design did not function. c , d , H929-induced IFN-γ in replicate 1 against replicate 2, measured on separate plates; dashed line, identity; dotted lines, lower limit of detection; R 2 , squared Pearson correlation of log 10 values for wells above that limit (c, 74 wells; d, 73 wells). c , The primary T-cell re-screen of , which plots replicate 1: library designs (light gray circles), brs–ζ1–40 (orange diamond), BBζ (gray square) and negative controls (×). d , The BCMA CARs of : small open light-gray circles, non-peak E:T wells; filled circles, each design’s peak, as ranked in : brs–ζ1–40 (orange), krgr–ζ1–4-1bb (teal), BBζ (gray) and other designs (small, light gray). e , f , IFN-γ across the eight E:T ratios behind the peak values of (e; H929 targets, BCMA CARs; mean ± s.d. of the two replicate plates, or the single reading where only one exists) and (f; NALM6 targets, CD19 CARs; one well per E:T), with points joined without fitting: brs–ζ1–40 (orange diamonds), krgr–ζ1–4-1bb (teal triangles), BBζ (gray squares) and other designs (light gray circles).

    Article Snippet: NALM6 leukemia cells (ATCC, CRL-3273), which we transduced with firefly luciferase lentivirus (BPS Bioscience, 79692-P), and Raji lymphoma cells (ATCC, CCL-86) were cultured in RPMI-1640 with 10% FBS and 1% penicillin– streptomycin.

    Techniques: Membrane

    a , Highest IFN-γ across the E:T ratios of on each day. b , Killing IC50 on each day, the E:T at which the fitted H929 viability curves of cross 50%; triangles, days whose fits stay above 50% at the highest E:T. The values under b list the same IC50s (>20, above 50% at the highest E:T). c , Viability of NALM6 leukemia cells after co-culture with the lentivirally transduced CAR T cells of , and with brs–ζ1–40 CAR T cells from the same experiment, across twelve 2-fold E:T ratios, as 100 minus killing relative to mock T cells; curves, descriptive four-parameter fits as in .

    Journal: bioRxiv

    Article Title: Refactored intracellular domains enhance CAR expression and function

    doi: 10.64898/2026.10.28.762481

    Figure Lengend Snippet: a , Highest IFN-γ across the E:T ratios of on each day. b , Killing IC50 on each day, the E:T at which the fitted H929 viability curves of cross 50%; triangles, days whose fits stay above 50% at the highest E:T. The values under b list the same IC50s (>20, above 50% at the highest E:T). c , Viability of NALM6 leukemia cells after co-culture with the lentivirally transduced CAR T cells of , and with brs–ζ1–40 CAR T cells from the same experiment, across twelve 2-fold E:T ratios, as 100 minus killing relative to mock T cells; curves, descriptive four-parameter fits as in .

    Article Snippet: NALM6 leukemia cells (ATCC, CRL-3273), which we transduced with firefly luciferase lentivirus (BPS Bioscience, 79692-P), and Raji lymphoma cells (ATCC, CCL-86) were cultured in RPMI-1640 with 10% FBS and 1% penicillin– streptomycin.

    Techniques: Co-culture Assay

    ( A ) Overview of cytosolic formaldehyde (FA) catabolism. ( B ) Heatmap depicting Log10 of the 50% FA inhibitory concentration (IC 50 ) in the presence or absence of l -buthionine-sulfoximine (BSO) at concentrations of 25 μM (H2170 cells), 50 μM (Jurkat, Nalm6, K562, and LUDLU-1 cells) or 100 μM (HCT116, H1299, A549, and T98G cells). ( C ) Representative FA viability curves normalized (norm.) to 0 μM FA for H1299 and A549 cells [mean ± SEM, n = 5 (H1299), n = 6 (A549), and two-way ANOVA (Tukey test between untreated (UT) and 100 μM BSO); for H1299: ** P = 0.0016, **** P < 0.0001, and ** P = 0.0023]. ( D ) Glutathione (GSH) levels upon 24-hour exposure to BSO [same concentrations as (B)] (mean ± SEM, n represented as dots, t test comparison between UT and BSO; * P = 0.0142, ** P = 0.0073, **** P < 0.0001). ( E ) Colony survival assay (CSA) in HCT116, H1299, and A549 in the presence of FA and/or 3.12 μM BSO for H1299 cells and 6.25 μM BSO for both HCT116 and A549 cells [mean ± SEM, n represented as dots, one-way ANOVA (Tukey test); for HCT116: **** P < 0.0001; for H1299: * P = 0.0106 and ** P = 0.0033]. ( F ) Left: GSH quantification in A549 cells expressing a nontargeting-control sgRNA (sgNTC) or sgRNAs against GSS (sg GSS ). Right: Viability in response to FA [mean ± SEM, n = 3]. ( G ) Immunoblots in A549 cells carrying an empty vector (pEV) or a vector coding for wild-type KEAP1 (p KEAP1 ). ( H ) Viability curves for A549/pEV or A549/pKEAP1 cells exposed to different concentrations of FA in the presence of 100 μM BSO [mean ± SEM, n = 3 and two-way ANOVA (Tukey test between UT and 100 μM BSO); **** P < 0.0001]. ( I ) DNA-protein cross-link (DPC) accumulation in A549/pEV and A549/pKEAP1 cells exposed to 100 μM BSO for 48 hours and to the indicated concentrations of FA for 4 hours (mean ± SEM, n = 3, one-way ANOVA in each cell line corrected by Tukey test) . Created in BioRender. https://BioRender.com/tsuwhsf .

    Journal: Science Advances

    Article Title: NRF2 coordinates cystine import and glutathione use to sustain ferroptosis resistance and formaldehyde tolerance in cancer

    doi: 10.1126/sciadv.aea1431

    Figure Lengend Snippet: ( A ) Overview of cytosolic formaldehyde (FA) catabolism. ( B ) Heatmap depicting Log10 of the 50% FA inhibitory concentration (IC 50 ) in the presence or absence of l -buthionine-sulfoximine (BSO) at concentrations of 25 μM (H2170 cells), 50 μM (Jurkat, Nalm6, K562, and LUDLU-1 cells) or 100 μM (HCT116, H1299, A549, and T98G cells). ( C ) Representative FA viability curves normalized (norm.) to 0 μM FA for H1299 and A549 cells [mean ± SEM, n = 5 (H1299), n = 6 (A549), and two-way ANOVA (Tukey test between untreated (UT) and 100 μM BSO); for H1299: ** P = 0.0016, **** P < 0.0001, and ** P = 0.0023]. ( D ) Glutathione (GSH) levels upon 24-hour exposure to BSO [same concentrations as (B)] (mean ± SEM, n represented as dots, t test comparison between UT and BSO; * P = 0.0142, ** P = 0.0073, **** P < 0.0001). ( E ) Colony survival assay (CSA) in HCT116, H1299, and A549 in the presence of FA and/or 3.12 μM BSO for H1299 cells and 6.25 μM BSO for both HCT116 and A549 cells [mean ± SEM, n represented as dots, one-way ANOVA (Tukey test); for HCT116: **** P < 0.0001; for H1299: * P = 0.0106 and ** P = 0.0033]. ( F ) Left: GSH quantification in A549 cells expressing a nontargeting-control sgRNA (sgNTC) or sgRNAs against GSS (sg GSS ). Right: Viability in response to FA [mean ± SEM, n = 3]. ( G ) Immunoblots in A549 cells carrying an empty vector (pEV) or a vector coding for wild-type KEAP1 (p KEAP1 ). ( H ) Viability curves for A549/pEV or A549/pKEAP1 cells exposed to different concentrations of FA in the presence of 100 μM BSO [mean ± SEM, n = 3 and two-way ANOVA (Tukey test between UT and 100 μM BSO); **** P < 0.0001]. ( I ) DNA-protein cross-link (DPC) accumulation in A549/pEV and A549/pKEAP1 cells exposed to 100 μM BSO for 48 hours and to the indicated concentrations of FA for 4 hours (mean ± SEM, n = 3, one-way ANOVA in each cell line corrected by Tukey test) . Created in BioRender. https://BioRender.com/tsuwhsf .

    Article Snippet: Nalm6 cells and Jurkat cells were obtained from DSMZ, while K562 were sourced from ATCC.

    Techniques: Concentration Assay, Comparison, Clonogenic Cell Survival Assay, Expressing, Control, Western Blot, Plasmid Preparation

    (A). DT intoxication pathway. DT consists of a catalytic domain, a translocation domain and a receptor binding domain. Upon binding to its targeting receptor HBEGF, DT undergoes receptor-mediated endocytosis. The translocation domain facilitates endosomal escape and cytosolic delivery of the catalytic domain, which subsequently catalyzes the ADP ribosylation of elongation factor 2. This leads to inhibition of protein synthesis and ultimately cell death. (B). Schematic of DT-based immunotoxins. The native RBD of DT is swapped with a binder to cancer-associated receptors. CD123-, HER3- and HER2-targeted ITs are designed using either nanobodies (CD123) or affibodies (HER2 and HER3). For each targeted receptor, low- and high-affinity binders were formatted as either monovalent or bivalent RBDs, generating four different RBD configurations. (C). The impacts of affinity and avidity tuning on the therapeutic window of ITs. For each targeted receptor, ITs were tested on in paired receptor-high (red) and a receptor-low (gray) cell lines, with receptor abundance quantified by flow cytometry and indicated above each cell line. Representative dose-response curves are shown for the low-affinity monovalent ITs. The therapeutic window was defined as the ratio of EC50 in receptor-low over receptor-high cells. Black bars indicate the magnitude of therapeutic window, and the edge of the black bar represents the EC50 means. n=3, biological replicates.

    Journal: bioRxiv

    Article Title: Attenuating payload potency expands the therapeutic window of immunotoxins

    doi: 10.64898/2026.09.27.754776

    Figure Lengend Snippet: (A). DT intoxication pathway. DT consists of a catalytic domain, a translocation domain and a receptor binding domain. Upon binding to its targeting receptor HBEGF, DT undergoes receptor-mediated endocytosis. The translocation domain facilitates endosomal escape and cytosolic delivery of the catalytic domain, which subsequently catalyzes the ADP ribosylation of elongation factor 2. This leads to inhibition of protein synthesis and ultimately cell death. (B). Schematic of DT-based immunotoxins. The native RBD of DT is swapped with a binder to cancer-associated receptors. CD123-, HER3- and HER2-targeted ITs are designed using either nanobodies (CD123) or affibodies (HER2 and HER3). For each targeted receptor, low- and high-affinity binders were formatted as either monovalent or bivalent RBDs, generating four different RBD configurations. (C). The impacts of affinity and avidity tuning on the therapeutic window of ITs. For each targeted receptor, ITs were tested on in paired receptor-high (red) and a receptor-low (gray) cell lines, with receptor abundance quantified by flow cytometry and indicated above each cell line. Representative dose-response curves are shown for the low-affinity monovalent ITs. The therapeutic window was defined as the ratio of EC50 in receptor-low over receptor-high cells. Black bars indicate the magnitude of therapeutic window, and the edge of the black bar represents the EC50 means. n=3, biological replicates.

    Article Snippet: Human breast adenocarcinoma cell line SK-BR-3, human colorectal cancer cell line HCT116, human non-small cell lung cancer cell line NCI-H358, human acute myeloid leukemia cell line MOLM13, and human acute lymphoblastic leukemia cell line NALM6 were purchased from ATCC.

    Techniques: Translocation Assay, Binding Assay, Inhibition, Flow Cytometry